About Acrivon Therapeutics, Inc. Common Stock
https://www.acrivon.comAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
CEO
Peter Blume-Jensen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Cantor Fitzgerald
Overweight
Jones Trading
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:8.34M
Value:$15.26M
SANDS CAPITAL VENTURES, LLC
Shares:2.12M
Value:$3.88M
CITADEL ADVISORS LLC
Shares:1.54M
Value:$2.82M
Summary
Showing Top 3 of 51
About Acrivon Therapeutics, Inc. Common Stock
https://www.acrivon.comAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.39M ▼ | $-18.23M ▲ | 0% | $-0.47 ▲ | $-17.93M ▲ |
| Q2-2025 | $0 | $22.35M ▲ | $-21.01M ▼ | 0% | $-0.55 ▼ | $-20.71M ▼ |
| Q1-2025 | $0 | $21.35M ▼ | $-19.68M ▲ | 0% | $-0.51 ▲ | $-19.37M ▲ |
| Q4-2024 | $0 | $24.65M ▼ | $-22.83M ▼ | 0% | $-0.6 ▼ | $-22.53M ▲ |
| Q3-2024 | $0 | $25.14M | $-22.44M | 0% | $-0.59 | $-24.89M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $129.25M ▼ | $145.3M ▼ | $16.7M ▲ | $128.6M ▼ |
| Q2-2025 | $137.42M ▼ | $158.58M ▼ | $15.55M ▼ | $143.04M ▼ |
| Q1-2025 | $149.63M ▼ | $176.35M ▼ | $15.96M ▼ | $160.39M ▼ |
| Q4-2024 | $179.48M ▼ | $196.59M ▼ | $19.8M ▲ | $176.79M ▼ |
| Q3-2024 | $187.45M | $214.68M | $17.79M | $196.89M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-18.23M ▲ | $-12.28M ▲ | $5.91M ▼ | $-117K ▼ | $-6.49M ▼ | $-13.18M ▲ |
| Q2-2025 | $-21.01M ▼ | $-16.61M ▲ | $19.45M ▲ | $-97K ▲ | $2.74M ▲ | $-17.1M ▲ |
| Q1-2025 | $-19.68M ▲ | $-19.54M ▼ | $19.21M ▲ | $-343K ▲ | $-664K ▲ | $-19.59M ▼ |
| Q4-2024 | $-22.83M ▼ | $-17.36M ▼ | $14.41M ▼ | $-647K ▲ | $-3.6M ▼ | $-18.19M ▲ |
| Q3-2024 | $-22.44M | $-17.32M | $16.01M | $-1.5M | $-2.59M | $-18.31M |
CEO
Peter Blume-Jensen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Cantor Fitzgerald
Overweight
Jones Trading
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:8.34M
Value:$15.26M
SANDS CAPITAL VENTURES, LLC
Shares:2.12M
Value:$3.88M
CITADEL ADVISORS LLC
Shares:1.54M
Value:$2.82M
Summary
Showing Top 3 of 51